Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVELTY-R: Hypofractionated RT + NALIRIF + Enlonstobart + Target Therapy in Rectal Cancer
NCT07183865Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2025
- Primary completion
- Mar 2030
- Modality
- Small Molecules, Lipid-based Nanoparticles, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PBI-1308 and nanoliposomal irinotecan in rectal cancer, sponsored by Fudan University. Primary endpoint: Local objective response rate at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
PBI-1308nanoliposomal irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07183865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183865.